Cargando…

Rasagiline, sleep quality and well-being in Parkinson’s disease: a pilot study

Sleep disordersand excessive daytime sleepiness are among the commonest nonmotor symptoms in Parkinson disease (PD) and can contribute to significantly lower quality of life in affected patients. Various antiparkinson drugs exert a relevant influence on sleep quality, daily vigilance and well-being....

Descripción completa

Detalles Bibliográficos
Autores principales: Mutti, Carlotta, Sarnataro, Roberta Beatrice, Beretta, Jessica, Enzo, Poli, Negrotti, Anna, Rausa, Francesco, Pizzarotti, Silvia, Parrino, Liborio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948046/
https://www.ncbi.nlm.nih.gov/pubmed/35334012
http://dx.doi.org/10.1007/s10072-022-06008-9
_version_ 1784674582836281344
author Mutti, Carlotta
Sarnataro, Roberta Beatrice
Beretta, Jessica
Enzo, Poli
Negrotti, Anna
Rausa, Francesco
Pizzarotti, Silvia
Parrino, Liborio
author_facet Mutti, Carlotta
Sarnataro, Roberta Beatrice
Beretta, Jessica
Enzo, Poli
Negrotti, Anna
Rausa, Francesco
Pizzarotti, Silvia
Parrino, Liborio
author_sort Mutti, Carlotta
collection PubMed
description Sleep disordersand excessive daytime sleepiness are among the commonest nonmotor symptoms in Parkinson disease (PD) and can contribute to significantly lower quality of life in affected patients. Various antiparkinson drugs exert a relevant influence on sleep quality, daily vigilance and well-being. In the latest years, administration of monoamine oxidase type B inhibitor (iMAO-B) medications in PD, especially rasagiline, has gained importance due to the hypothesized neuroprotective effect of these agents. Whereas the ‘wakepromoting’ effect of selegine, due to its activating amphetamine-like compounds, has been already described, less is known regarding the effect of rasagiline, a world-wide used iMAO-B drug. A pilot study was carried out to analyze the effects of rasagiline on sleep and healthrelated quality of life in a small cohort of PD patients. According to our results, PD patients treated with rasagiline referred better sleep quality, required less frequently hypnotic medication, complained of lower daytime sleepiness and presented higher scores in social functioning, perceived energy levels and emotional well-being. Albeit limited by the small sample size, our study suggests an intriguing role of rasagiline in improving sleep and quality of life in PD patients. Further studies are necessary to confirm our preliminary observations.
format Online
Article
Text
id pubmed-8948046
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-89480462022-03-25 Rasagiline, sleep quality and well-being in Parkinson’s disease: a pilot study Mutti, Carlotta Sarnataro, Roberta Beatrice Beretta, Jessica Enzo, Poli Negrotti, Anna Rausa, Francesco Pizzarotti, Silvia Parrino, Liborio Neurol Sci Original Article Sleep disordersand excessive daytime sleepiness are among the commonest nonmotor symptoms in Parkinson disease (PD) and can contribute to significantly lower quality of life in affected patients. Various antiparkinson drugs exert a relevant influence on sleep quality, daily vigilance and well-being. In the latest years, administration of monoamine oxidase type B inhibitor (iMAO-B) medications in PD, especially rasagiline, has gained importance due to the hypothesized neuroprotective effect of these agents. Whereas the ‘wakepromoting’ effect of selegine, due to its activating amphetamine-like compounds, has been already described, less is known regarding the effect of rasagiline, a world-wide used iMAO-B drug. A pilot study was carried out to analyze the effects of rasagiline on sleep and healthrelated quality of life in a small cohort of PD patients. According to our results, PD patients treated with rasagiline referred better sleep quality, required less frequently hypnotic medication, complained of lower daytime sleepiness and presented higher scores in social functioning, perceived energy levels and emotional well-being. Albeit limited by the small sample size, our study suggests an intriguing role of rasagiline in improving sleep and quality of life in PD patients. Further studies are necessary to confirm our preliminary observations. Springer International Publishing 2022-03-25 2022 /pmc/articles/PMC8948046/ /pubmed/35334012 http://dx.doi.org/10.1007/s10072-022-06008-9 Text en © Fondazione Società Italiana di Neurologia 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Mutti, Carlotta
Sarnataro, Roberta Beatrice
Beretta, Jessica
Enzo, Poli
Negrotti, Anna
Rausa, Francesco
Pizzarotti, Silvia
Parrino, Liborio
Rasagiline, sleep quality and well-being in Parkinson’s disease: a pilot study
title Rasagiline, sleep quality and well-being in Parkinson’s disease: a pilot study
title_full Rasagiline, sleep quality and well-being in Parkinson’s disease: a pilot study
title_fullStr Rasagiline, sleep quality and well-being in Parkinson’s disease: a pilot study
title_full_unstemmed Rasagiline, sleep quality and well-being in Parkinson’s disease: a pilot study
title_short Rasagiline, sleep quality and well-being in Parkinson’s disease: a pilot study
title_sort rasagiline, sleep quality and well-being in parkinson’s disease: a pilot study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948046/
https://www.ncbi.nlm.nih.gov/pubmed/35334012
http://dx.doi.org/10.1007/s10072-022-06008-9
work_keys_str_mv AT mutticarlotta rasagilinesleepqualityandwellbeinginparkinsonsdiseaseapilotstudy
AT sarnatarorobertabeatrice rasagilinesleepqualityandwellbeinginparkinsonsdiseaseapilotstudy
AT berettajessica rasagilinesleepqualityandwellbeinginparkinsonsdiseaseapilotstudy
AT enzopoli rasagilinesleepqualityandwellbeinginparkinsonsdiseaseapilotstudy
AT negrottianna rasagilinesleepqualityandwellbeinginparkinsonsdiseaseapilotstudy
AT rausafrancesco rasagilinesleepqualityandwellbeinginparkinsonsdiseaseapilotstudy
AT pizzarottisilvia rasagilinesleepqualityandwellbeinginparkinsonsdiseaseapilotstudy
AT parrinoliborio rasagilinesleepqualityandwellbeinginparkinsonsdiseaseapilotstudy